Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab

Almirall acquires option to license rights to develop and commercialize lebrikizumab for atopic dermatitis in Europe Dermira to receive an option fee of $30 MM Lebrikizumab is an investigational anti-IL-13 monoclonal antibody currently in Phase 2b development with topline data expected by early April 2019

The release as fetched from its publisher. almirall.com ↗